Stocks
Boston Scientific Financial Statements (BSX) |
||||||||||
| Boston Scientificsmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 25.02.2020 | 23.02.2021 | 23.02.2022 | 23.02.2023 | 20.02.2024 | 01.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 10 735 | 9 913 | 11 888 | 12 682 | 14 240 | 14 707 | |||
| Operating Income, bln rub | 1 518 | 1 044 | 2 043 | 1 649 | 2 343 | 2 484 | ||||
| EBITDA, bln rub | ? | 2 082 | 1 833 | 2 784 | 2 800 | 3 620 | 3 616 | |||
| Net profit, bln rub | ? | 4 700 | -140.0 | 1 041 | 698.0 | 1 593 | 1 771 | |||
| OCF, bln rub | ? | 1 836 | 1 508 | 1 870 | 1 526 | 2 503 | 2 477 | |||
| CAPEX, bln rub | ? | 461.0 | 376.0 | 554.0 | 612.0 | 800.0 | 924.0 | |||
| FCF, bln rub | ? | 1 375 | 1 132 | 1 316 | 914.0 | 1 703 | 1 553 | |||
| Dividend payout, bln rub | 0.000 | 28.0 | 55.0 | 55.0 | 28.0 | 14.0 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 5.28% | 7.88% | 1.76% | 0.79% | ||||
| OPEX, bln rub | 5 814 | 5 719 | 6 304 | 6 646 | 7 478 | 7 644 | ||||
| Cost of production, bln rub | 3 181 | 3 510 | 3 760 | 4 003 | 4 345 | 4 538 | ||||
| R&D, bln rub | 1 174 | 1 143 | 1 204 | 1 323 | 1 414 | 1 444 | ||||
| Interest expenses, bln rub | 473.0 | 361.0 | 341.0 | 470.0 | 265.0 | 270.0 | ||||
| Assets, bln rub | 30 565 | 30 778 | 32 230 | 32 470 | 35 136 | 36 669 | ||||
| Net Assets, bln rub | ? | 13 877 | 15 327 | 16 623 | 17 574 | 19 281 | 19 925 | |||
| Debt, bln rub | 10 277 | 9 539 | 9 451 | 9 282 | 9 492 | 11 001 | ||||
| Cash, bln rub | 217.0 | 1 734 | 1 925 | 928.0 | 865.0 | 2 329 | ||||
| Net debt, bln rub | 10 060 | 7 805 | 7 526 | 8 354 | 8 627 | 8 672 | ||||
| Ordinary share price, rub | 45.2 | 36.0 | 42.5 | 46.3 | 57.8 | 52.5 | ||||
| Number of ordinary shares, mln | 1 392 | 1 417 | 1 422 | 1 431 | 1 453 | 1 468 | ||||
| Market cap, bln rub | 62 924 | 50 930 | 60 419 | 66 189 | 83 998 | 77 120 | ||||
| EV, bln rub | ? | 72 984 | 58 735 | 67 945 | 74 543 | 92 625 | 85 792 | |||
| Book value, bln rub | -4 185 | -540 | -1 485 | -1 249 | -1 109 | -273 | ||||
| EPS, rub | ? | 3.38 | -0.10 | 0.73 | 0.49 | 1.10 | 1.21 | |||
| FCF/share, rub | 0.99 | 0.80 | 0.93 | 0.64 | 1.17 | 1.06 | ||||
| BV/share, rub | -3.01 | -0.38 | -1.04 | -0.87 | -0.76 | -0.19 | ||||
| EBITDA margin, % | ? | 19.4% | 18.5% | 23.4% | 22.1% | 25.4% | 24.6% | |||
| Net margin, % | ? | 43.8% | -1.41% | 8.76% | 5.50% | 11.2% | 12.0% | |||
| FCF yield, % | ? | 2.19% | 2.22% | 2.18% | 1.38% | 2.03% | 2.01% | |||
| ROE, % | ? | 33.9% | -0.91% | 6.26% | 3.97% | 8.26% | 8.89% | |||
| ROA, % | ? | 15.4% | -0.45% | 3.23% | 2.15% | 4.53% | 4.83% | |||
| P/E | ? | 13.4 | -363.8 | 58.0 | 94.8 | 52.7 | 43.5 | |||
| P/FCF | 45.8 | 45.0 | 45.9 | 72.4 | 49.3 | 49.7 | ||||
| P/S | ? | 5.86 | 5.14 | 5.08 | 5.22 | 5.90 | 5.24 | |||
| P/BV | ? | -15.0 | -94.3 | -40.7 | -53.0 | -75.7 | -282.5 | |||
| EV/EBITDA | ? | 35.1 | 32.0 | 24.4 | 26.6 | 25.6 | 23.7 | |||
| Debt/EBITDA | 4.83 | 4.26 | 2.70 | 2.98 | 2.38 | 2.40 | ||||
| R&D/CAPEX, % | 254.7% | 304.0% | 217.3% | 216.2% | 176.8% | 156.3% | ||||
| CAPEX/Revenue, % | 4.29% | 3.79% | 4.66% | 4.83% | 5.62% | 6.28% | ||||
| Boston Scientific shareholders | ||||||||||
